Cytotherapy

Papers
(The H4-Index of Cytotherapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies154
Crowdfunding, stem cell interventions and autism spectrum disorder: comparing campaigns related to an international “stem cell clinic” and US academic medical center67
Editorial Board50
Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma45
Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo44
Modeling the selective growth advantage of genetically variant human pluripotent stem cells to identify opportunities for manufacturing process control37
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity33
Infusion reactions in natural killer cell immunotherapy: a retrospective review33
A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy33
Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease31
Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights29
Table of Contents29
Subscription information26
Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program26
Aims and Scope23
Table of Contents22
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial22
Subscription information22
Limited Quality of Life Sacrifice for Optimizing long-term Survival: The Impact of p-ALG Compared to r-ATG in High-Risk Hematological Malignancy Patients Undergoing Matched Sibling Donor Transplantati22
The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products21
Subscription information21
0.15998196601868